Perspective for prophylaxis and treatment of cervical cancer: an immunological approach

Int Rev Immunol. 2012 Feb;31(1):3-21. doi: 10.3109/08830185.2011.637254.


As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alphapapillomavirus / immunology*
  • Animals
  • Carcinoma / prevention & control
  • Carcinoma / therapy*
  • Cell Transformation, Neoplastic
  • Cell Transformation, Viral
  • Female
  • Humans
  • Immunotherapy, Active*
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines / therapeutic use*
  • Sexually Transmitted Diseases, Viral / complications
  • Sexually Transmitted Diseases, Viral / prevention & control
  • Sexually Transmitted Diseases, Viral / virology
  • Uterine Cervical Neoplasms / prevention & control
  • Uterine Cervical Neoplasms / therapy*


  • Papillomavirus Vaccines